In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.

ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online.  As in the past, they provide abstracts online via the conference website.  The scientific program will take place May 29 through May 31.

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™

We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).

Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute.

The IWMF is proud to welcome two new members to its Scientific Advisory Committee (SAC) chaired by Dr. Steven Ansell of the Mayo Clinic and Dr. Stephen Treon of the Dana-Farber Cancer Institute. The new members, Dr. Jorge Castillo from Dana-Farber, Boston, USA, and Dr. Efstathios Kastritis of Athens, Greece, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.